Special Requirements for Immunosuppressive Drugs

MLN Matters Number: MM10370
Related Change Request (CR) Number: 10370
Related CR Release Date: December 8, 2017
Effective Date: August 1, 2016
Related CR Transmittal Number: R3932CP
Implementation Date: March 9, 2018

Note: This article was revised on March 28, 2018, to add links to SE17032 and MM10235. SE17032 reminds pharmacy billing staff of the appropriate process for billing Medicare for immunosuppressive drugs using the KX modifier. MM10235 is based on CR10235 which updates language in the "Medicare Claims Processing Manual," to remove a double negative statement and provide clear guidance to suppliers for when you may bill Medicare for immunosuppressive drugs. All other information is unchanged.

PROVIDER TYPE AFFECTED

This MLN Matters Article is intended for physicians, providers and suppliers billing Durable Medical Equipment Medicare Administrative Contractors (DME MACs) for immunosuppressive drugs provided to Medicare beneficiaries.

WHAT YOU NEED TO KNOW

The Centers for Medicare & Medicaid Services (CMS) is revising the Part B date of service requirements for the first immunosuppressive drug claim after the beneficiary is discharged from an inpatient stay as follows: in order to allow payment for a claim for an immunosuppressive drug that is mailed by a supplier either 1 or 2 days before a beneficiary is discharged from an inpatient facility, the supplier may enter the date of discharge as the date of service. The manual changes in CR10370 are effective as of August 1, 2016. Make sure your billing staffs are aware of the revision.

BACKGROUND

Under Medicare Part B, the date of service on a supplier’s immunosuppressive drug claim must be the date the supplier actually delivered or mailed the item. Thus, if a supplier mails a prescription shortly before the end of a beneficiary’s inpatient stay and uses the mailing date as the date of service, the claim processing system will reject the supplier’s claim because the claim’s date of service precedes the beneficiary’s date of discharge. As a result, beneficiaries whose immunosuppressive drug prescriptions are mailed on the day of discharge from an inpatient facility may be at risk for an interruption in their immunosuppressive drug therapy.
CMS is revising the date of service requirements for the first immunosuppressive drug claim after the beneficiary is discharged from an inpatient stay as follows: in order to allow payment for a claim for an immunosuppressive drug that is mailed by a supplier either 1 or 2 days before a beneficiary is discharged from an inpatient facility, the supplier may enter the date of discharge as the date of service.

The Manual update associated with CR10370 is based on the section titled Special Optional Requirements for Immunosuppressive Drugs in CR 2731, which was issued on June 27, 2003. CR 2731 is available at https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/downloads/R1804B3.pdf. The manual changes in CR10370 are limited to the date of service requirement for immunosuppressive drugs paid under Medicare Part B and do not alter coverage provisions, claim submission, or delivery requirements for immunosuppressive drugs.

Inpatient facilities (for example hospitals) are responsible for providing drugs during a beneficiary’s inpatient stay. However, once the beneficiary has returned home, Part B suppliers (including pharmacies) provide immunosuppressive drugs, and the DME MACs make payments for Part B covered immunosuppressive drugs.

Under normal circumstances, the date of service listed on a supplier’s claim must be the date the supplier actually delivered or mailed the item. However, suppliers that utilize mail-order delivery may wish to mail immunosuppressive drug prescriptions 1 or 2 days prior to the date that a beneficiary will be discharged from an inpatient facility, so that the drugs will be available at the beneficiary’s home immediately after the beneficiary returns. In this situation, the systems will reject the supplier’s immunosuppressive drug claim because the date of service precedes the beneficiary’s date of discharge; the hospital remains responsible for the provision of immunosuppressive drugs while the beneficiary is still an inpatient.

In order to obtain payment for immunosuppressive drug prescriptions that have been mailed 1 or 2 days before a beneficiary’s discharge, the supplier may enter the date of discharge as the date of service on the first claim it submits for the beneficiary after the beneficiary is discharged from an inpatient facility. Note that this is an optional, not mandatory, process. If the supplier chooses not to mail the immunosuppressive drug(s) prior to the beneficiary’s date of discharge from the hospital, they may wait for the beneficiary to be discharged before delivering the drugs, and follow all applicable Medicare and DME MAC rules for immunosuppressive drug billing (for example, the date of service will be the date of delivery).

Note that the following conditions also apply:

1. The facility remains responsible for all immunosuppressive drugs required by the beneficiary for the duration of the beneficiary’s inpatient stay. The supplier must not receive separate payment for immunosuppressive drugs prior to the date the beneficiary is discharged.
2. The supplier must not mail or otherwise dispense the drugs any earlier than 2 days before the beneficiary is discharged. It is the supplier’s responsibility to confirm the beneficiary’s discharge date if they choose to take advantage of this option.
3. The supplier must not submit a claim for payment prior to the beneficiary’s date of discharge.
4. The beneficiary’s discharge must be to a qualified place of service (for example, home, or custodial facility), but not to another facility (for example, inpatient hospital or skilled nursing facility) that does not qualify as the beneficiary’s home.

**ADDITIONAL INFORMATION**


If you have any questions, please contact your MAC at their toll-free number. That number is available at [https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/](https://www.cms.gov/Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS-Compliance-Programs/Review-Contractor-Directory-Interactive-Map/)

**DOCUMENT HISTORY**

<table>
<thead>
<tr>
<th>Date of Change</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>March 28, 2018</td>
<td>This article was revised to add links to SE17032 and MM10235. SE17032 reminds pharmacy billing staff of the appropriate process for billing Medicare for immunosuppressive drugs using the KX modifier. MM10235 is based on CR10235 which updates language in the “Medicare Claims Processing Manual,” to remove a double negative statement and provide clear guidance to suppliers for when you may bill Medicare for immunosuppressive drugs.</td>
</tr>
<tr>
<td>December 8, 2017</td>
<td>Initial article released</td>
</tr>
</tbody>
</table>

Disclaimer: This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2016 American Medical Association. All rights reserved.

Copyright © 2017, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816 or Laryssa Marshall at (312) 893-6814. You may also contact us at ub04@healthforum.com

The American Hospital Association (the “AHA”) has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.